Future developments in immunotherapy for treatment of biliary tract cancer

Aiwu Ruth He, MD, Georgetown Lombardi Comprehensive Cancer Center, Washington DC, USA, comments on future avenues in research for the diagnosis and treatment of biliary tract cancer. Specifically, Dr He comments on the potential identification of novel biomarkers which may aid in the selection of patients with biliary tract cancer who could benefit from treatment with durvalumab plus chemotherapy. Moreover, personalized therapy and fibroblast growth factor receptor (FGFR) inhibitors for the treatment of biliary tract cancer are discussed. This interview took place at the European Society for Medical Oncology World Congress on Gastrointestinal Cancer (ESMO WCGIC) 2022 in Barcelona, Spain.